Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upLizza Hendriks, Martin Reck, Giulia Veronesi et al.|Annals of Oncology|2023Cited by 782
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 studyAntonio Passaro, Byoung Chul Cho|Annals of Oncology|2023Cited by 384
Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLCByoung Chul Cho, Patricia Lorenzini, Shun Lu et al.|New England Journal of Medicine|2024Cited by 369
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSAEnriqueta Felip, S.-H. Lee, Byoung Chul Cho et al.|Annals of Oncology|2024Cited by 81
Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practiceAntonio Passaro, Filippo de Marinis|OncoTargets and Therapy|2016Cited by 24